Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 182

1.

Scleral Fixation of the Fluocinolone Acetonide Implant in Eyes with Severe Iris-Lens Diaphragm Disruption and Recalcitrant CME: The Fluocinolone-Loop-Anchoring Technique (FLAT).

Herold TR, Liegl R, Koenig S, Almarzooqi A, Priglinger SG, Wolf A.

Ophthalmol Ther. 2020 Feb 13. doi: 10.1007/s40123-020-00232-2. [Epub ahead of print]

PMID:
32056140
2.

Plasticity in growth behavior of patients' acute myeloid leukemia stem cells growing in mice.

Ebinger S, Zeller C, Carlet M, Senft D, Bagnoli JW, Liu WH, Rothenberg-Thurley M, Enard W, Metzeler KH, Herold T, Spiekermann K, Vick B, Jeremias I.

Haematologica. 2020 Feb 6. pii: haematol.2019.226282. doi: 10.3324/haematol.2019.226282. [Epub ahead of print] No abstract available.

3.

Gender-related differences in patients treated with intravitreal anti-vascular endothelial growth factor medication for diabetic macular oedema.

Schiefelbein J, Müller M, Kern C, Herold T, Liegl R, Fasler K, Jeliazkova D, Priglinger S, Kortuem KU.

Eur J Ophthalmol. 2020 Jan 14:1120672119899627. doi: 10.1177/1120672119899627. [Epub ahead of print]

PMID:
31937122
4.

Screening of Pleural Mesothelioma Cell Lines for Kinase Activity May Identify New Mechanisms of Therapy Resistance in Patients Receiving Platin-Based Chemotherapy.

Borchert S, Suckrau PM, Wessolly M, Mairinger E, Hegedus B, Hager T, Herold T, Eberhardt WEE, Wohlschlaeger J, Aigner C, Bankfalvi A, Schmid KW, Walter RFH, Mairinger FD.

J Oncol. 2019 Dec 23;2019:2902985. doi: 10.1155/2019/2902985. eCollection 2019.

5.

The clinical mutatome of core binding factor leukemia.

Opatz S, Bamopoulos SA, Metzeler KH, Herold T, Ksienzyk B, Bräundl K, Tschuri S, Vosberg S, Konstandin NP, Wang C, Hartmann L, Graf A, Krebs S, Blum H, Schneider S, Thiede C, Middeke JM, Stölzel F, Röllig C, Schetelig J, Ehninger G, Krämer A, Braess J, Görlich D, Sauerland MC, Berdel WE, Wörmann BJ, Hiddemann W, Spiekermann K, Bohlander SK, Greif PA.

Leukemia. 2020 Jan 2. doi: 10.1038/s41375-019-0697-0. [Epub ahead of print]

PMID:
31896782
6.

The long non-coding RNA Cancer Susceptibility 15 is induced by Isocitrate Dehydrogenase mutations and maintains an immature phenotype in adult acute myeloid leukemia.

Grasedieck S, Ruess C, Krowiorz K, Lux S, Pochert N, Schwarzer A, Klusmann JH, Jongen-Lavrencic M, Herold T, Bullinger L, Pollack JR, Rouhi A, Kuchenbauer F.

Haematologica. 2020 Jan 2. pii: haematol.2019.235291. doi: 10.3324/haematol.2019.235291. [Epub ahead of print] No abstract available.

7.

[New treatment for chronic lymphocytic leukemia].

Herold T, Nitschmann S, von Bergwelt M.

Internist (Berl). 2020 Jan;61(1):110-112. doi: 10.1007/s00108-019-00706-x. German. No abstract available.

PMID:
31848648
8.

New insights into intranuclear inclusions in thyroid carcinoma: Association with autophagy and with BRAFV600E mutation.

Schwertheim S, Theurer S, Jastrow H, Herold T, Ting S, Westerwick D, Bertram S, Schaefer CM, Kälsch J, Baba HA, Schmid KW.

PLoS One. 2019 Dec 16;14(12):e0226199. doi: 10.1371/journal.pone.0226199. eCollection 2019.

9.

Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation.

Wiesweg M, Herold T, Metzenmacher M, Eberhardt WE, Reis H, Darwiche K, Aigner C, Stuschke M, Herrmann K, Nensa F, Schildhaus HU, Schuler M.

Lung Cancer. 2020 Jan;139:165-168. doi: 10.1016/j.lungcan.2019.11.020. Epub 2019 Nov 26.

PMID:
31809977
10.

The ParaHox gene Cdx4 induces acute erythroid leukemia in mice.

Thoene S, Mandal T, Vegi NM, Quintanilla-Martinez L, Rösler R, Wiese S, Metzeler KH, Herold T, Haferlach T, Döhner K, Döhner H, Schwarzmüller L, Klingmüller U, Buske C, Rawat VPS, Feuring-Buske M.

Blood Adv. 2019 Nov 26;3(22):3729-3739. doi: 10.1182/bloodadvances.2019000761.

11.

Allelic Imbalance of Recurrently Mutated Genes in Acute Myeloid Leukaemia.

Batcha AMN, Bamopoulos SA, Kerbs P, Kumar A, Jurinovic V, Rothenberg-Thurley M, Ksienzyk B, Philippou-Massier J, Krebs S, Blum H, Schneider S, Konstandin N, Bohlander SK, Heckman C, Kontro M, Hiddemann W, Spiekermann K, Braess J, Metzeler KH, Greif PA, Mansmann U, Herold T.

Sci Rep. 2019 Aug 13;9(1):11796. doi: 10.1038/s41598-019-48167-4.

12.

Clinical and preclinical characterization of CD99 isoforms in acute myeloid leukemia.

Vaikari VP, Du Y, Wu S, Zhang T, Metzeler K, Batcha AMN, Herold T, Hiddemann W, Akhtari M, Alachkar H.

Haematologica. 2019 Aug 1. pii: haematol.2018.207001. doi: 10.3324/haematol.2018.207001. [Epub ahead of print]

13.

KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy.

Mühlenberg T, Ketzer J, Heinrich MC, Grunewald S, Marino-Enriquez A, Trautmann M, Hartmann W, Wardelmann E, Treckmann J, Worm K, Bertram S, Herold T, Schildhaus HU, Glimm H, Stenzinger A, Brors B, Horak P, Hohenberger P, Fröhling S, Fletcher JA, Bauer S.

Mol Cancer Ther. 2019 Nov;18(11):1985-1996. doi: 10.1158/1535-7163.MCT-18-1224. Epub 2019 Jul 15.

PMID:
31308077
14.

Nuclear factor of activated T-cells, NFATC1, governs FLT3ITD-driven hematopoietic stem cell transformation and a poor prognosis in AML.

Solovey M, Wang Y, Michel C, Metzeler KH, Herold T, Göthert JR, Ellenrieder V, Hessmann E, Gattenlöhner S, Neubauer A, Pavlinic D, Benes V, Rupp O, Burchert A.

J Hematol Oncol. 2019 Jul 8;12(1):72. doi: 10.1186/s13045-019-0765-y.

15.

The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia.

Angenendt L, Bormann E, Pabst C, Alla V, Görlich D, Braun L, Dohlich K, Schwöppe C, Bohlander SK, Arteaga MF, Wethmar K, Hartmann W, Angenendt A, Kessler T, Mesters RM, Stelljes M, Rothenberg-Thurley M, Spiekermann K, Hébert J, Sauvageau G, Valk PJM, Löwenberg B, Serve H, Müller-Tidow C, Lenz G, Wörmann BJ, Sauerland MC, Hiddemann W, Berdel WE, Krug U, Metzeler KH, Mikesch JH, Herold T, Schliemann C.

Leukemia. 2019 Dec;33(12):2830-2841. doi: 10.1038/s41375-019-0505-x. Epub 2019 Jun 10.

PMID:
31182782
16.

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose.

Jilg S, Hauch RT, Kauschinger J, Buschhorn L, Odinius TO, Dill V, Müller-Thomas C, Herold T, Prodinger PM, Schmidt B, Hempel D, Bassermann F, Peschel C, Götze KS, Höckendorf U, Haferlach T, Jost PJ.

Exp Hematol Oncol. 2019 Apr 16;8:9. doi: 10.1186/s40164-019-0133-1. eCollection 2019.

17.

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.

Borchert S, Wessolly M, Schmeller J, Mairinger E, Kollmeier J, Hager T, Mairinger T, Herold T, Christoph DC, Walter RFH, Eberhardt WEE, Plönes T, Wohlschlaeger J, Aigner C, Schmid KW, Mairinger FD.

BMC Cancer. 2019 Jan 30;19(1):108. doi: 10.1186/s12885-019-5314-0.

18.

Comprehensive characterization of RB1 mutant and MYCN amplified retinoblastoma cell lines.

Schwermer M, Hiber M, Dreesmann S, Rieb A, Theißen J, Herold T, Schramm A, Temming P, Steenpass L.

Exp Cell Res. 2019 Feb 15;375(2):92-99. doi: 10.1016/j.yexcr.2018.12.018. Epub 2018 Dec 22.

19.

Impact of RAS mutation subtype on clinical outcome-a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer.

Wiesweg M, Kasper S, Worm K, Herold T, Reis H, Sara L, Metzenmacher M, Abendroth A, Darwiche K, Aigner C, Wedemeyer HH, Helfritz FA, Stuschke M, Schumacher B, Markus P, Paul A, Rahmann S, Schmid KW, Schuler M.

Oncogene. 2019 Apr;38(16):2953-2966. doi: 10.1038/s41388-018-0634-0. Epub 2018 Dec 19.

PMID:
30568222
20.

Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPA.

Konstandin NP, Pastore F, Herold T, Dufour A, Rothenberg-Thurley M, Hinrichsen T, Ksienzyk B, Tschuri S, Schneider S, Hoster E, Berdel WE, Woermann BJ, Sauerland MC, Braess J, Bohlander SK, Klein HG, Hiddemann W, Metzeler KH, Spiekermann K.

Blood Adv. 2018 Oct 23;2(20):2724-2731. doi: 10.1182/bloodadvances.2018016840.

21.

Priority-Lasso: a simple hierarchical approach to the prediction of clinical outcome using multi-omics data.

Klau S, Jurinovic V, Hornung R, Herold T, Boulesteix AL.

BMC Bioinformatics. 2018 Sep 12;19(1):322. doi: 10.1186/s12859-018-2344-6.

22.

Rapid and Highly Sensitive Detection of Therapeutically Relevant Oncogenic Driver Mutations in EBUS-TBNA Specimens From Patients With Lung Adenocarcinoma.

Oezkan F, Herold T, Darwiche K, Eberhardt WEE, Worm K, Christoph DC, Wiesweg M, Freitag L, Schmid KW, Theegarten D, Hager T, Koenig MJ, He K, Taube C, Schuler M, Breitenbuecher F.

Clin Lung Cancer. 2018 Nov;19(6):e879-e884. doi: 10.1016/j.cllc.2018.08.016. Epub 2018 Aug 22.

PMID:
30206042
23.

3-year-data of combined navigated laser photocoagulation (Navilas) and intravitreal ranibizumab compared to ranibizumab monotherapy in DME patients.

Herold TR, Langer J, Vounotrypidis E, Kernt M, Liegl R, Priglinger SG.

PLoS One. 2018 Aug 23;13(8):e0202483. doi: 10.1371/journal.pone.0202483. eCollection 2018.

24.

Extracorporeal Membrane Oxygenation in Predominantly Leuco- and Thrombocytopenic Haematologic/Oncologic Patients with Acute Respiratory Distress Syndrome - a Single-Centre Experience.

Stecher SS, Beyer G, Goni E, Tischer J, Herold T, Schulz C, Op den Winkel M, Stemmler HJ, Lippl S.

Oncol Res Treat. 2018;41(9):539-543. doi: 10.1159/000489718. Epub 2018 Aug 17.

25.

Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia.

Hornung R, Jurinovic V, Batcha AMN, Bamopoulos SA, Rothenberg-Thurley M, Amler S, Sauerland MC, Berdel WE, Wörmann BJ, Bohlander SK, Braess J, Hiddemann W, Lehmann S, Mareschal S, Spiekermann K, Metzeler KH, Herold T, Boulesteix AL.

Sci Rep. 2018 Jul 26;8(1):11293. doi: 10.1038/s41598-018-29593-2.

26.

Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia.

Schranz K, Hubmann M, Harin E, Vosberg S, Herold T, Metzeler KH, Rothenberg-Thurley M, Janke H, Bräundl K, Ksienzyk B, Batcha AMN, Schaaf S, Schneider S, Bohlander SK, Görlich D, Berdel WE, Wörmann BJ, Braess J, Krebs S, Hiddemann W, Mansmann U, Spiekermann K, Greif PA.

Oncotarget. 2018 Jul 10;9(53):30128-30145. doi: 10.18632/oncotarget.25729. eCollection 2018 Jul 10.

27.

Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML.

Haubner S, Perna F, Köhnke T, Schmidt C, Berman S, Augsberger C, Schnorfeil FM, Krupka C, Lichtenegger FS, Liu X, Kerbs P, Schneider S, Metzeler KH, Spiekermann K, Hiddemann W, Greif PA, Herold T, Sadelain M, Subklewe M.

Leukemia. 2019 Jan;33(1):64-74. doi: 10.1038/s41375-018-0180-3. Epub 2018 Jun 26.

28.

Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older.

Prassek VV, Rothenberg-Thurley M, Sauerland MC, Herold T, Janke H, Ksienzyk B, Konstandin NP, Goerlich D, Krug U, Faldum A, Berdel WE, Wörmann B, Braess J, Schneider S, Subklewe M, Bohlander SK, Hiddemann W, Spiekermann K, Metzeler KH.

Haematologica. 2018 Nov;103(11):1853-1861. doi: 10.3324/haematol.2018.191536. Epub 2018 Jun 14.

29.

Pneumokokkensepsis und Osteoidosteom – eine seltene Koinzidenz.

Kakkassery M, Rehmenklau-Bremer L, Herold T.

Rofo. 2018 Nov;190(11):1070-1072. doi: 10.1055/a-0620-9034. Epub 2018 Jun 6. German. No abstract available.

PMID:
29874699
30.

Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data.

Reis H, Krafft U, Niedworok C, Módos O, Herold T, Behrendt M, Al-Ahmadie H, Hadaschik B, Nyirady P, Szarvas T.

Dis Markers. 2018 Mar 12;2018:7308168. doi: 10.1155/2018/7308168. eCollection 2018. Review.

31.

Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.

Reis H, van der Vos KE, Niedworok C, Herold T, Módos O, Szendrői A, Hager T, Ingenwerth M, Vis DJ, Behrendt MA, de Jong J, van der Heijden MS, Peyronnet B, Mathieu R, Wiesweg M, Ablat J, Okon K, Tolkach Y, Keresztes D, Nagy N, Bremmer F, Gaisa NT, Chlosta P, Kriegsmann J, Kovalszky I, Timar J, Kristiansen G, Radzun HJ, Knüchel R, Schuler M, Black PC, Rübben H, Hadaschik BA, Schmid KW, van Rhijn BWG, Nyirády P, Szarvas T.

Int J Cancer. 2018 Oct 1;143(7):1764-1773. doi: 10.1002/ijc.31547. Epub 2018 May 10.

32.

MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy.

Reis H, Metzenmacher M, Goetz M, Savvidou N, Darwiche K, Aigner C, Herold T, Eberhardt WE, Skiba C, Hense J, Virchow I, Westerwick D, Bogner S, Ting S, Kasper S, Stuschke M, Nensa F, Herrmann K, Hager T, Schmid KW, Schuler M, Wiesweg M.

Clin Lung Cancer. 2018 Jul;19(4):e441-e463. doi: 10.1016/j.cllc.2018.03.010. Epub 2018 Mar 17.

PMID:
29631966
33.

Phosphorylation of p70 Ribosomal Protein S6 Kinase β-1 is an Independent Prognostic Parameter in Metastatic Colorectal Cancer.

Wiesweg M, Reis H, Köster T, Goetz M, Worm K, Herold T, Paul A, Dechêne A, Schumacher B, Markus P, Virchow I, Kostbade K, Wolf N, Zaun G, Metzenmacher M, Schmid KW, Schuler M, Kasper S.

Clin Colorectal Cancer. 2018 Jun;17(2):e331-e352. doi: 10.1016/j.clcc.2018.02.003. Epub 2018 Feb 17.

PMID:
29526493
34.

Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study.

Nørgaard CH, Jakobsen LH, Gentles AJ, Dybkær K, El-Galaly TC, Bødker JS, Schmitz A, Johansen P, Herold T, Spiekermann K, Brown JR, Klitgaard JL, Johnsen HE, Bøgsted M.

PLoS One. 2018 Mar 7;13(3):e0193249. doi: 10.1371/journal.pone.0193249. eCollection 2018.

35.

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.

Rothenberg-Thurley M, Amler S, Goerlich D, Köhnke T, Konstandin NP, Schneider S, Sauerland MC, Herold T, Hubmann M, Ksienzyk B, Zellmeier E, Bohlander SK, Subklewe M, Faldum A, Hiddemann W, Braess J, Spiekermann K, Metzeler KH.

Leukemia. 2018 Jul;32(7):1598-1608. doi: 10.1038/s41375-018-0034-z. Epub 2018 Feb 23.

36.

Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients.

Greif PA, Hartmann L, Vosberg S, Stief SM, Mattes R, Hellmann I, Metzeler KH, Herold T, Bamopoulos SA, Kerbs P, Jurinovic V, Schumacher D, Pastore F, Bräundl K, Zellmeier E, Ksienzyk B, Konstandin NP, Schneider S, Graf A, Krebs S, Blum H, Neumann M, Baldus CD, Bohlander SK, Wolf S, Görlich D, Berdel WE, Wörmann BJ, Hiddemann W, Spiekermann K.

Clin Cancer Res. 2018 Apr 1;24(7):1716-1726. doi: 10.1158/1078-0432.CCR-17-2344. Epub 2018 Jan 12.

37.

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.

Rothenberg-Thurley M, Amler S, Goerlich D, Köhnke T, Konstandin NP, Schneider S, Sauerland MC, Herold T, Hubmann M, Ksienzyk B, Zellmeier E, Bohlander SK, Subklewe M, Faldum A, Hiddemann W, Braess J, Spiekermann K, Metzeler KH.

Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.350. [Epub ahead of print]

PMID:
29249818
38.

A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia.

Herold T, Jurinovic V, Batcha AMN, Bamopoulos SA, Rothenberg-Thurley M, Ksienzyk B, Hartmann L, Greif PA, Phillippou-Massier J, Krebs S, Blum H, Amler S, Schneider S, Konstandin N, Sauerland MC, Görlich D, Berdel WE, Wörmann BJ, Tischer J, Subklewe M, Bohlander SK, Braess J, Hiddemann W, Metzeler KH, Mansmann U, Spiekermann K.

Haematologica. 2018 Mar;103(3):456-465. doi: 10.3324/haematol.2017.178442. Epub 2017 Dec 14.

39.

COMPLIANCE AND ADHERENCE OF PATIENTS WITH DIABETIC MACULAR EDEMA TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN DAILY PRACTICE.

Weiss M, Sim DA, Herold T, Schumann RG, Liegl R, Kern C, Kreutzer T, Schiefelbein J, Rottmann M, Priglinger S, KortUEm KU.

Retina. 2018 Dec;38(12):2293-2300. doi: 10.1097/IAE.0000000000001892.

PMID:
29068914
40.

Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer.

Thiem S, Herold T, Krafft U, Bremmer F, Tolkach Y, Szász AM, Kriegsmann J, Gaisa NT, Niedworok C, Szarvas T, Reis H.

Pathol Int. 2017 Dec;67(12):597-601. doi: 10.1111/pin.12594. Epub 2017 Oct 19.

PMID:
29047227
41.

A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients.

Beck D, Thoms JAI, Palu C, Herold T, Shah A, Olivier J, Boelen L, Huang Y, Chacon D, Brown A, Babic M, Hahn C, Perugini M, Zhou X, Huntly BJ, Schwarzer A, Klusmann JH, Berdel WE, Wörmann B, Büchner T, Hiddemann W, Bohlander SK, To LB, Scott HS, Lewis ID, D'Andrea RJ, Wong JWH, Pimanda JE.

Leukemia. 2018 Feb;32(2):263-272. doi: 10.1038/leu.2017.210. Epub 2017 Jul 4.

PMID:
28674423
42.

webKnossos: efficient online 3D data annotation for connectomics.

Boergens KM, Berning M, Bocklisch T, Bräunlein D, Drawitsch F, Frohnhofen J, Herold T, Otto P, Rzepka N, Werkmeister T, Werner D, Wiese G, Wissler H, Helmstaedter M.

Nat Methods. 2017 Jul;14(7):691-694. doi: 10.1038/nmeth.4331. Epub 2017 Jun 12.

PMID:
28604722
43.

NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma.

Tiedje V, Ting S, Herold T, Synoracki S, Latteyer S, Moeller LC, Zwanziger D, Stuschke M, Fuehrer D, Schmid KW.

Oncotarget. 2017 Jun 27;8(26):42613-42620. doi: 10.18632/oncotarget.17300.

44.

Philadelphia-Like Acute Lymphoblastic Leukemia in Adults.

Herold T, Gökbuget N.

Curr Oncol Rep. 2017 May;19(5):31. doi: 10.1007/s11912-017-0589-2. Review.

PMID:
28361222
45.

Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.

Bredemeier M, Kasimir-Bauer S, Kolberg HC, Herold T, Synoracki S, Hauch S, Edimiris P, Bankfalvi A, Tewes M, Kimmig R, Aktas B.

Mol Med Rep. 2017 May;15(5):2957-2968. doi: 10.3892/mmr.2017.6415. Epub 2017 Mar 30.

46.

Eukaryotic elongation factor 2 is a prognostic marker and its kinase a potential therapeutic target in HCC.

Pott LL, Hagemann S, Reis H, Lorenz K, Bracht T, Herold T, Skryabin BV, Megger DA, Kälsch J, Weber F, Sitek B, Baba HA.

Oncotarget. 2017 Feb 14;8(7):11950-11962. doi: 10.18632/oncotarget.14447.

47.

A 17-gene stemness score for rapid determination of risk in acute leukaemia.

Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, Arruda A, Popescu A, Gupta V, Schimmer AD, Schuh AC, Yee KW, Bullinger L, Herold T, Görlich D, Büchner T, Hiddemann W, Berdel WE, Wörmann B, Cheok M, Preudhomme C, Dombret H, Metzeler K, Buske C, Löwenberg B, Valk PJ, Zandstra PW, Minden MD, Dick JE, Wang JC.

Nature. 2016 Dec 15;540(7633):433-437. doi: 10.1038/nature20598. Epub 2016 Dec 7.

PMID:
27926740
48.

Complement cascade gene expression defines novel prognostic subgroups of acute myeloid leukemia.

Laverdière I, Boileau M, Herold T, Rak J, Berdel WE, Wörmann B, Hiddemann W, Spiekermann K, Bohlander SK, Eppert K.

Exp Hematol. 2016 Nov;44(11):1039-1043.e10. doi: 10.1016/j.exphem.2016.07.012. Epub 2016 Jul 26.

PMID:
27473565
49.

Acute myeloid leukemia with del(9q) is characterized by frequent mutations of NPM1, DNMT3A, WT1 and low expression of TLE4.

Herold T, Metzeler KH, Vosberg S, Hartmann L, Jurinovic V, Opatz S, Konstandin NP, Schneider S, Zellmeier E, Ksienzyk B, Graf A, Krebs S, Blum H, Cristina Sauerland M, Büchner T, Berdel WE, Wörmann BJ, Mansmann U, Hiddemann W, Bohlander SK, Spiekermann K, Greif PA.

Genes Chromosomes Cancer. 2017 Jan;56(1):75-86. doi: 10.1002/gcc.22418. Epub 2016 Oct 25.

PMID:
27636548
50.

Enzyme pretreatment of fats, oil and grease from restaurant waste to prolong septic soil treatment system effectiveness.

Dong Y, Safferman SI, Ostahowski J, Herold T, Panter R.

J Environ Sci Health A Tox Hazard Subst Environ Eng. 2017 Jan 2;52(1):55-63. doi: 10.1080/10934529.2016.1229928. Epub 2016 Oct 11.

PMID:
27726482

Supplemental Content

Loading ...
Support Center